6,140 Shares in Oruka Therapeutics, Inc. (NASDAQ:ORKA) Purchased by AlphaCentric Advisors LLC

AlphaCentric Advisors LLC bought a new stake in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 6,140 shares of the company’s stock, valued at approximately $119,000.

Other hedge funds have also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. purchased a new position in Oruka Therapeutics during the 4th quarter valued at $144,000. Geode Capital Management LLC bought a new stake in shares of Oruka Therapeutics during the third quarter worth $343,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Oruka Therapeutics during the third quarter valued at $1,037,000. Wellington Management Group LLP bought a new position in shares of Oruka Therapeutics in the third quarter worth about $2,013,000. Finally, Janus Henderson Group PLC purchased a new position in Oruka Therapeutics in the 3rd quarter worth about $5,840,000. Institutional investors own 56.44% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a research report on Friday, February 7th. Wedbush reiterated an “outperform” rating and issued a $40.00 price target on shares of Oruka Therapeutics in a report on Tuesday, November 19th. Finally, Wolfe Research began coverage on Oruka Therapeutics in a report on Tuesday, February 4th. They set an “outperform” rating and a $20.00 price objective on the stock. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $39.86.

Oruka Therapeutics Stock Performance

Oruka Therapeutics stock opened at $11.18 on Tuesday. The stock has a market capitalization of $391.30 million, a price-to-earnings ratio of -1.79 and a beta of 0.77. The business’s fifty day moving average is $16.58. Oruka Therapeutics, Inc. has a twelve month low of $10.61 and a twelve month high of $53.88.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.